Cargando…

Assessment of the tocolytic nifedipine in preclinical primary models of preterm birth

Spontaneous preterm birth is the leading cause of perinatal morbidity and mortality. Tocolytics are drugs used in cases of imminent preterm birth to inhibit uterine contractions. Nifedipine is a calcium channel blocking agent used to delay threatened spontaneous preterm birth, however, has limited e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arman, Bridget M., Binder, Natalie K., de Alwis, Natasha, Beard, Sally, Debruin, Danielle A., Hayes, Alan, Tong, Stephen, Kaitu’u-Lino, Tu’uhevaha J., Hannan, Natalie J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079980/ https://www.ncbi.nlm.nih.gov/pubmed/37024530 http://dx.doi.org/10.1038/s41598-023-31077-x

Ejemplares similares

Assessment of the Proton Pump Inhibitor, Esomeprazole Magnesium Hydrate and Trihydrate, on Pathophysiological Markers of Preeclampsia in Preclinical Human Models of Disease
por: de Alwis, Natasha, et al.
Publicado: (2022)

The Regulation of Endothelin-1 in Pregnancies Complicated by Gestational Diabetes: Uncovering the Vascular Effects of Insulin
por: Fato, Bianca R., et al.
Publicado: (2023)

Investigating the Effects of Atrial Natriuretic Peptide on the Maternal Endothelium to Determine Potential Implications for Preeclampsia
por: Binder, Natalie K., et al.
Publicado: (2023)

Serum Collected from Preeclamptic Pregnancies Drives Vasoconstriction of Human Omental Arteries—A Novel Ex Vivo Model of Preeclampsia for Therapeutic Development
por: Fato, Bianca R., et al.
Publicado: (2022)

Pre-Clinical Investigation of Cardioprotective Beta-Blockers as a Therapeutic Strategy for Preeclampsia
por: Binder, Natalie K., et al.
Publicado: (2021)

Therapeutic interventions: The importance of including diseased and healthy samples in preclinical studies
por: Tu'uhevaha J., Kaitu'u-Lino
Publicado: (2019)

Melatonin enhances antioxidant molecules in the placenta, reduces secretion of soluble fms-like tyrosine kinase 1 (sFLT) from primary trophoblast but does not rescue endothelial dysfunction: An evaluation of its potential to treat preeclampsia
por: Hannan, Natalie J., et al.
Publicado: (2018)

Actions of Esomeprazole on the Maternal Vasculature in Lean and Obese Pregnant Mice with Impaired Nitric Oxide Synthesis: A Model of Preeclampsia
por: de Alwis, Natasha, et al.
Publicado: (2022)

A comparison of sample collection methods for quantifying cell-free fetal neurodevelopment transcripts in amniotic fluid
por: Hui, Lisa, et al.
Publicado: (2016)

Measuring circulating miRNAs in early pregnancy could identify fetuses’ destined to undergrow and be at increased risk of stillbirth
por: Tong, Stephen, et al.
Publicado: (2020)

Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction – implications for treating preeclampsia
por: Kaitu’u-Lino, Tu’uhevaha J., et al.
Publicado: (2018)

Placental Growth Factor Is Secreted by the Human Endometrium and Has Potential Important Functions during Embryo Development and Implantation
por: Binder, Natalie K., et al.
Publicado: (2016)

A Bioplex Analysis of Cytokines and Chemokines in First Trimester Maternal Plasma to Screen for Predictors of Miscarriage
por: Hannan, Natalie J., et al.
Publicado: (2014)

The L-NAME mouse model of preeclampsia and impact to long-term maternal cardiovascular health
por: de Alwis, Natasha, et al.
Publicado: (2022)

NR4A2 expression is not altered in placentas from cases of growth restriction or preeclampsia, but is reduced in hypoxic cytotrophoblast
por: de Alwis, Natasha, et al.
Publicado: (2021)

Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta
por: Brownfoot, Fiona C., et al.
Publicado: (2016)

Clinical tools and biomarkers to predict preeclampsia
por: MacDonald, Teresa M, et al.
Publicado: (2021)

DAAM2 is elevated in the circulation and placenta in pregnancies complicated by fetal growth restriction and is regulated by hypoxia
por: de Alwis, Natasha, et al.
Publicado: (2021)

Placental OLAH Levels Are Altered in Fetal Growth Restriction, Preeclampsia and Models of Placental Dysfunction
por: de Alwis, Natasha, et al.
Publicado: (2022)

Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction – implications as a preeclampsia treatment
por: Hannan, Natalie J., et al.
Publicado: (2017)

Associations Between Soluble fms‐Like Tyrosine Kinase‐1 and Placental Growth Factor and Disease Severity Among Women With Preterm Eclampsia and Preeclampsia
por: Hastie, Roxanne, et al.
Publicado: (2022)

Evaluation of ADAM-12 as a Diagnostic Biomarker of Ectopic Pregnancy in Women with a Pregnancy of Unknown Location
por: Horne, Andrew W., et al.
Publicado: (2012)

MMP-15 Is Upregulated in Preeclampsia, but Does Not Cleave Endoglin to Produce Soluble Endoglin
por: Kaitu’u-Lino, Tu’uhevaha J., et al.
Publicado: (2012)

Serum Concentrations of Soluble Flt-1 Are Decreased among Women with a Viable Fetus and No Symptoms of Miscarriage Destined for Pregnancy Loss
por: Kaitu'u-Lino, Tu'uhevaha J., et al.
Publicado: (2012)

Plasma MIC-1 and PAPP-A Levels Are Decreased among Women Presenting to an Early Pregnancy Assessment Unit, Have Fetal Viability Confirmed but Later Miscarry
por: Kaitu’u-Lino, Tu’uhevaha J., et al.
Publicado: (2013)

Maternal Serum Macrophage Inhibitory Cytokine-1 as a Biomarker for Ectopic Pregnancy in Women with a Pregnancy of Unknown Location
por: Skubisz, Monika M., et al.
Publicado: (2013)

Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy
por: Hastie, Roxanne, et al.
Publicado: (2018)

A double blind, randomised, placebo-controlled trial to evaluate the efficacy of metformin to treat preterm pre-eclampsia (PI2 Trial): study protocol
por: Cluver, Catherine, et al.
Publicado: (2019)

Circulating GATA2 mRNA is decreased among women destined to develop preeclampsia and may be of endothelial origin
por: Whigham, Carole-Anne, et al.
Publicado: (2019)

Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction
por: Brownfoot, Fiona C., et al.
Publicado: (2019)

Placental galectin-3 is reduced in early-onset preeclampsia
por: Kandel, Manju, et al.
Publicado: (2022)

ELABELA/APELA Levels Are Not Decreased in the Maternal Circulation or Placenta among Women with Preeclampsia
por: Pritchard, Natasha, et al.
Publicado: (2018)

MicroRNAs 363 and 149 are differentially expressed in the maternal circulation preceding a diagnosis of preeclampsia
por: Whigham, Carole-Anne, et al.
Publicado: (2020)

Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial
por: Cluver, Catherine A, et al.
Publicado: (2021)

Circulating SPINT1 Is Reduced in a Preeclamptic Cohort with Co-Existing Fetal Growth Restriction
por: Murphy, Ciara N., et al.
Publicado: (2022)

Plasma lipids are dysregulated preceding diagnosis of preeclampsia or delivery of a growth restricted infant
por: Bartho, Lucy A., et al.
Publicado: (2023)

PSG7 and 9 (Pregnancy‐Specific β‐1 Glycoproteins 7 and 9): Novel Biomarkers for Preeclampsia
por: Kandel, Manju, et al.
Publicado: (2022)

Paternal Expressed Gene 10 (PEG10) is decreased in early-onset preeclampsia
por: Baird, Lydia, et al.
Publicado: (2023)

Circulating mRNAs are differentially expressed in pregnancies with severe placental insufficiency and at high risk of stillbirth
por: Hannan, Natalie J., et al.
Publicado: (2020)

Circulating Chemerin Is Elevated in Women With Preeclampsia
por: Bartho, Lucy A, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7r29ru05oqj7gq0ca32etlhkjm